BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li X, Liu Y, Tian H. Current Developments in Pt(IV) Prodrugs Conjugated with Bioactive Ligands. Bioinorg Chem Appl 2018;2018:8276139. [PMID: 30402082 DOI: 10.1155/2018/8276139] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 7.5] [Reference Citation Analysis]
Number Citing Articles
1 Jimenez-macias J, Lee Y, Miller E, Finkelberg T, Zdioruk M, Berger G, Farquhar C, Nowicki M, Cho C, Fedeles B, Loas A, Pentelute B, Lawler S. A Pt(IV)-conjugated brain penetrant macrocyclic peptide shows pre-clinical efficacy in glioblastoma. Journal of Controlled Release 2022;352:623-636. [DOI: 10.1016/j.jconrel.2022.10.051] [Reference Citation Analysis]
2 Larasati L, Lestari WW, Firdaus M. Dual-Action Pt(IV) Prodrugs and Targeted Delivery in Metal-Organic Frameworks: Overcoming Cisplatin Resistance and Improving Anticancer Activity. BCSJ 2022;95:1561-1577. [DOI: 10.1246/bcsj.20220218] [Reference Citation Analysis]
3 Scoditti S, Mazzone G, Sanna N, Sicilia E. Computational Exploration of the Synergistic Anticancer Effect of a Multi-Action Ru(II)-Pt(IV) Conjugate. Inorg Chem 2022. [PMID: 35900874 DOI: 10.1021/acs.inorgchem.2c02223] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Johan AN, Li Y. Development of Photoremovable Linkers as a Novel Strategy to Improve the Pharmacokinetics of Drug Conjugates and Their Potential Application in Antibody–Drug Conjugates for Cancer Therapy. Pharmaceuticals 2022;15:655. [DOI: 10.3390/ph15060655] [Reference Citation Analysis]
5 Barth MC, Lange S, Häfner N, Ueberschaar N, Görls H, Runnebaum IB, Weigand W. Synthesis and characterization of thiocarbonato-linked platinum(IV) complexes. Dalton Trans 2022;51:5567-76. [PMID: 35311885 DOI: 10.1039/d2dt00318j] [Reference Citation Analysis]
6 Ravera M, Gabano E, McGlinchey MJ, Osella D. Pt(IV) antitumor prodrugs: dogmas, paradigms, and realities. Dalton Trans 2022;51:2121-34. [PMID: 35015025 DOI: 10.1039/d1dt03886a] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
7 Song M, Cui M, Liu K. Therapeutic strategies to overcome cisplatin resistance in ovarian cancer. European Journal of Medicinal Chemistry 2022. [DOI: 10.1016/j.ejmech.2022.114205] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
8 Lu Y, Zhu D, Le Q, Wang Y, Wang W. Ruthenium-based antitumor drugs and delivery systems from monotherapy to combination therapy. Nanoscale 2022. [DOI: 10.1039/d2nr02994d] [Reference Citation Analysis]
9 Predarska I, Saoud M, Morgan I, Eichhorn T, Kaluđerović GN, Hey-Hawkins E. Cisplatin-cyclooxygenase inhibitor conjugates, free and immobilised in mesoporous silica SBA-15, prove highly potent against triple-negative MDA-MB-468 breast cancer cell line. Dalton Trans 2021. [PMID: 34877948 DOI: 10.1039/d1dt03265h] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Peng K, Liang B, Liu W, Mao Z. What blocks more anticancer platinum complexes from experiment to clinic: Major problems and potential strategies from drug design perspectives. Coordination Chemistry Reviews 2021;449:214210. [DOI: 10.1016/j.ccr.2021.214210] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 18.0] [Reference Citation Analysis]
11 Mu M, Zhan J, Dai X, Gao H. Research progress of azido-containing Pt(IV) antitumor compounds. Eur J Med Chem 2021;227:113927. [PMID: 34695775 DOI: 10.1016/j.ejmech.2021.113927] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
12 Jiang M, Chu Y, Yang T, Li W, Zhang Z, Sun H, Liang H, Yang F. Developing a Novel Indium(III) Agent Based on Liposomes to Overcome Cisplatin-Induced Resistance in Breast Cancer by Multitargeting the Tumor Microenvironment Components. J Med Chem 2021;64:14587-602. [PMID: 34609868 DOI: 10.1021/acs.jmedchem.1c01068] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
13 Niu B, Liao K, Zhou Y, Wen T, Quan G, Pan X, Wu C. Application of glutathione depletion in cancer therapy: Enhanced ROS-based therapy, ferroptosis, and chemotherapy. Biomaterials 2021;277:121110. [PMID: 34482088 DOI: 10.1016/j.biomaterials.2021.121110] [Cited by in Crossref: 71] [Cited by in F6Publishing: 81] [Article Influence: 71.0] [Reference Citation Analysis]
14 Piorecka K, Kurjata J, Stanczyk WA. Nanoarchitectonics: Complexes and Conjugates of Platinum Drugs with Silicon Containing Nanocarriers. An Overview. Int J Mol Sci 2021;22:9264. [PMID: 34502173 DOI: 10.3390/ijms22179264] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
15 Fiekkies JTR, Fourie E, Erasmus E. Cisplatin-functionalized nanodiamonds: preparation and characterization, with potential antineoplastic application. Appl Nanosci 2021;11:2235-45. [DOI: 10.1007/s13204-021-01955-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Lang T, Li N, Zhang J, Li Y, Rong R, Fu Y. Prodrug-based nano-delivery strategy to improve the antitumor ability of carboplatin in vivo and in vitro. Drug Deliv 2021;28:1272-80. [PMID: 34176381 DOI: 10.1080/10717544.2021.1938754] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
17 Krasnovskaya O, Spector D, Erofeev A, Gorelkin P, Akasov R, Skvortsov D, Trigub A, Vlasova K, Semkina A, Zyk N, Beloglazkina E, Majouga A. Alternative mechanism of action of the DNP PtIV prodrug: intracellular cisplatin release and the mitochondria-mediated apoptotic pathway. Dalton Trans 2021;50:7922-7. [PMID: 34037020 DOI: 10.1039/d1dt00898f] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
18 Szumilak M, Wiktorowska-Owczarek A, Stanczak A. Hybrid Drugs-A Strategy for Overcoming Anticancer Drug Resistance? Molecules 2021;26:2601. [PMID: 33946916 DOI: 10.3390/molecules26092601] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 15.0] [Reference Citation Analysis]
19 Scoditti S, Vigna V, Dabbish E, Sicilia E. Iodido equatorial ligands influence on the mechanism of action of Pt(IV) and Pt(II) anti-cancer complexes: A DFT computational study. J Comput Chem 2021;42:608-19. [PMID: 33469953 DOI: 10.1002/jcc.26483] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
20 Phadnis PP. Synthesis and Development of Platinum-Based Anticancer Drugs. Handbook on Synthesis Strategies for Advanced Materials 2021. [DOI: 10.1007/978-981-16-1892-5_14] [Reference Citation Analysis]
21 Studer V, Anghel N, Desiatkina O, Felder T, Boubaker G, Amdouni Y, Ramseier J, Hungerbühler M, Kempf C, Heverhagen JT, Hemphill A, Ruprecht N, Furrer J, Păunescu E. Conjugates Containing Two and Three Trithiolato-Bridged Dinuclear Ruthenium(II)-Arene Units as In Vitro Antiparasitic and Anticancer Agents. Pharmaceuticals (Basel) 2020;13:E471. [PMID: 33339451 DOI: 10.3390/ph13120471] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
22 Chen Y, Wang Q, Li Z, Liu Z, Zhao Y, Zhang J, Liu M, Wang Z, Li D, Han J. Naproxen platinum(iv) hybrids inhibiting cycloxygenases and matrix metalloproteinases and causing DNA damage: synthesis and biological evaluation as antitumor agents in vitro and in vivo. Dalton Trans 2020;49:5192-204. [PMID: 32236281 DOI: 10.1039/d0dt00424c] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 11.5] [Reference Citation Analysis]
23 Yu C, Wang Z, Sun Z, Zhang L, Zhang W, Xu Y, Zhang JJ. Platinum-Based Combination Therapy: Molecular Rationale, Current Clinical Uses, and Future Perspectives. J Med Chem 2020;63:13397-412. [PMID: 32813515 DOI: 10.1021/acs.jmedchem.0c00950] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 11.0] [Reference Citation Analysis]
24 Shi H, Imberti C, Clarkson GJ, Sadler PJ. Axial functionalisation of photoactive diazido platinum(iv) anticancer complexes. Inorg Chem Front 2020;7:3533-40. [PMID: 33786191 DOI: 10.1039/D0QI00685H] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
25 Tabrizi L, Thompson K, Mnich K, Chintha C, Gorman AM, Morrison L, Luessing J, Lowndes NF, Dockery P, Samali A, Erxleben A. Novel Pt(IV) Prodrugs Displaying Antimitochondrial Effects. Mol Pharm 2020;17:3009-23. [PMID: 32628022 DOI: 10.1021/acs.molpharmaceut.0c00417] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
26 Zhang X, Liu L, Tang M, Li H, Guo X, Yang X. The effects of umbilical cord-derived macrophage exosomes loaded with cisplatin on the growth and drug resistance of ovarian cancer cells. Drug Dev Ind Pharm 2020;46:1150-62. [PMID: 32482115 DOI: 10.1080/03639045.2020.1776320] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 14.0] [Reference Citation Analysis]
27 Kitteringham E, Mckeon AM, O'dowd P, Devocelle M, Murphy BM, Griffith DM. Synthesis and characterisation of a novel mono functionalisable Pt(IV) oxaliplatin-type complex and its peptide conjugate. Inorganica Chimica Acta 2020;505:119492. [DOI: 10.1016/j.ica.2020.119492] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
28 Adams CJ, Meade TJ. Gd(iii)-Pt(iv) theranostic contrast agents for tandem MR imaging and chemotherapy. Chem Sci 2020;11:2524-30. [PMID: 34084418 DOI: 10.1039/c9sc05937g] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
29 Yudkina A, Sokolov M, Abramov P, Grin I, Zharkov D. Platinum Polyoxoniobates Form Adducts with DNA. Russ J Bioorg Chem 2019;45:641-6. [DOI: 10.1134/s1068162019060414] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Zhang S, Wang X, Guo Z. Rational design of anticancer platinum(IV) prodrugs. Medicinal Chemistry. Elsevier; 2020. pp. 149-82. [DOI: 10.1016/bs.adioch.2019.10.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
31 Ravera M, Gabano E, Mcglinchey MJ, Osella D. A view on multi-action Pt(IV) antitumor prodrugs. Inorganica Chimica Acta 2019;492:32-47. [DOI: 10.1016/j.ica.2019.04.025] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 16.0] [Reference Citation Analysis]
32 Ghosh S. Cisplatin: The first metal based anticancer drug. Bioorg Chem 2019;88:102925. [PMID: 31003078 DOI: 10.1016/j.bioorg.2019.102925] [Cited by in Crossref: 442] [Cited by in F6Publishing: 493] [Article Influence: 147.3] [Reference Citation Analysis]
33 Lee P, Lok C, Che C, Kao WJ. A Multifunctional Hydrogel Delivers Gold Compound and Inhibits Human Lung Cancer Xenograft. Pharm Res 2019;36. [DOI: 10.1007/s11095-019-2581-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]